This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Helpful, and short, which on this subject is harder than long.
Post #59 answers the question as asked. The question underneath it is different.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
Adding the caveat now so it does not have to be extracted later.
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
A weak preference rather than a position.
The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly schedule works. Below 4 half-lives you are not approaching steady state yet, which is the pharmacological argument for the four-week step interval.
On balance I think that is right, and I would not bet much on it.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
Not the whole picture, but the part of it I can speak to.
Worth separating two things that post #63 runs together.
The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.
The bit of semaglutide half-life that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
I would be cautious about generalising from the semaglutide half-life example above. It is a good example. It is one example.
The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.
Marking that as an opinion rather than a finding.
Adding the measurement that post #70 says would settle it.
Adding a reference point for semaglutide half-life. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
Post #72 describes the usual case. This is about the unusual one.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
A single observation, in a thread that deserves better than single observations.
Post #74 is right about the mechanism and I think understates the practical bit.
The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly schedule works. Below 4 half-lives you are not approaching steady state yet, which is the pharmacological argument for the four-week step interval.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
The confident version of this sentence would be wrong, so here is the hedged one.
Semaglutide half-life is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
Quietly grateful for the plain phrasing. Not every thread gets that.
I read post #76 twice before replying, because I had assumed the opposite.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
Where I part company with post #77, and it is a narrow parting.
The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a studied population, and individual clearance varies enough that a person's own steady state may be reached earlier or later than the population average implies.
Post #81 is the version of this I will quote in future. One addition.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
I would keep semaglutide half-life and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
Not disagreeing with anyone above, just adding the bit I keep having to look up.
Confirming post #85 from a second method, which matters more than confirming it from a second person.
Having read the whole semaglutide half-life thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.
That matches what I have seen, for whatever a single anecdote is worth.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
It is a small point and it changes the answer, which is an awkward combination.
On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and stability claims made about the first do not carry over to the second.
I would not lead a decision with this, but I would not ignore it either.